February 16, 2018
A Delaware federal judge dismantled a Merck & Co. unit's $2.5 billion jury verdict win over Gilead Sciences Inc. in an infringement suit over a hepatitis C drug patent, finding Friday that the patent's claims weren't specific enough for an experienced scientist to successfully re-create the formula.
September 22, 2017
A Delaware federal judge denied enhanced damages Friday to Merck & Co. unit Idenix after its $2.5 billion win over Gilead Sciences Inc. in a jury trial claiming infringement of a patent behind two blockbuster hepatitis C medicines, saying both the judge's own pretrial decisions and the jury's findings were "close."